Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment

Archives of Neurology

Volumn 67, Issue 4, 2010, Pages 440-446

  Albin, Roger L ^a,b   Koeppe, Robert A ^b   Burke, James F ^b   Giordani, Bruno ^c   Kilbourn, Michael R ^b   Gilman, Sid ^b   Frey, Kirk A ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DIHYDROTETRABENAZINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DEMENTIA; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; INTERMETHOD COMPARISON; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGE OF ONSET; AGED; AGED, 80 AND OVER; BINDING, COMPETITIVE; BRAIN MAPPING; CARBON RADIOISOTOPES; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; COGNITION DISORDERS; DEMENTIA; EARLY DIAGNOSIS; ENERGY METABOLISM; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TETRABENAZINE;

EID: 77950894521     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.34     Document Type: Article

References (74)

1. Knopman DS, DeKosky ST, Cummings JL, et al; Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: diagnosis of dementia (an evidence-based review). Neurology. 2001;56(9):1143-1153. (Pubitemid 32405708)
2. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54(5): 1050-1058. (Pubitemid 30151844)
3. Lopez OL, Litvan I, Catt KE, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology. 1999;53(6):1292-1299. (Pubitemid 29480090)
4. Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1999;66(2):184-188. (Pubitemid 29103519)
5. Rosen HJ, Hartikainen KM, Jagust W, et al. Utility of clinical criteria in differentiating frontotemporal lobar degeneration (FTLD) from AD. Neurology. 2002; 58(11):1608-1615. (Pubitemid 34602890)
6. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol. 2007;80(spec No 2):S160-S167. (Pubitemid 351799343)
7. Silverman DHS, Mosconi L, Ercoli L, Chen W, Small GW. Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Semin Nucl Med. 2008;38(4):251-261. (Pubitemid 351726326)
8. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32(4):486-510. (Pubitemid 40591181)
9. Silverman DHS, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286(17):2120-2127.
10. de Leon MJ, Ferris SH, George A, et al. Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease. J Cereb Blood Flow Metab. 1983;3(3):391-394. (Pubitemid 13017790)
11. Foster NL, Chase TN, Mansi L, et al. Cortical abnormalities in Alzheimer's disease. Ann Neurol. 1984;16(6):649-654.
12. Friedland RP, Brun A, Budinger TF. Pathological and positron emission tomographic correlations in Alzheimer's disease. Lancet. 1985;1(8422):228. (Pubitemid 15151499)
13. Koss E, Friedland RP, Ober BA, Jagust WJ. Differences in lateral hemispheric asymmetries of glucose utilization between early- and late-onset Alzheimer-type dementia. Am J Psychiatry. 1985;142(5):638-640. (Pubitemid 15034640)
14. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42(1):85-94. (Pubitemid 27304784)
15. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002; 17(1):302-316.
16. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002;159(5):738-745. (Pubitemid 34465046)
17. Small GW, Ercoli LM, Silverman DHS, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97(11):6037-6042.
18. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98(6):3334-3339. (Pubitemid 32220846)
19. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004;101(1):284-289. (Pubitemid 38084242)
20. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334(12):752-758. (Pubitemid 26089356)
21. Chételat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. 2003;60(8):1374-1377. (Pubitemid 36461002)
22. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol. 2003;54(3):343-351. (Pubitemid 37072036)
23. Arnáiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport. 2001;12(4):851-855. (Pubitemid 32222729)
24. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30(8):1104-1113. (Pubitemid 36988222)
25. Mosconi L, Sorbi S, Nacmias B, et al. Brain metabolic differences between sporadic and familial Alzheimer's disease. Neurology. 2003;61(8):1138-1140. (Pubitemid 37461956)
26. Herholz K, Nordberg A, Salmon E, et al. Impairment of neocortical metabolism predicts progression to Alzheimer's disease. Dement Geriatr Cogn Disord. 1999; 10(6):494-504. (Pubitemid 29512018)
27. Herholz K. PET studies in dementia. Ann Nucl Med. 2003;17(2):79-89.
28. Albin RL, Minoshima S, D'Amato C, Frey KA, Kuhl DE, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology. 1996;47(2):462-466. (Pubitemid 26324044)
29. Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50(3):358-365. (Pubitemid 32848738)
30. Higuchi M, Tashiro M, Arai H, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol. 2000; 162(2):247-256. (Pubitemid 30217720)
31. Salmon E, Garraux G, Delbeuck X, et al. Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia. Neuroimage. 2003;20(1): 435-440. (Pubitemid 37188532)
32. Diehl-Schmid J, Grimmer T, Drzezga A, et al. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging. 2007;28(1):42-50. (Pubitemid 44791637)
33. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improve accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007;130 (pt 10):2616-2635. (Pubitemid 47511706)
34. Ishii K, Sakamoto S, Sasaki M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med. 1998;39(11):1875-1878. (Pubitemid 28518885)
35. Jeong Y, Cho SS, Park JM, et al. 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med. 2005;46(2):233-239. (Pubitemid 43073429)
36. Tullberg M, Fletcher E, DeCarli C, et al. White matter lesions impair frontal lobe function regardless of their location. Neurology. 2004;63(2):246-253. (Pubitemid 38971122)
37. Kerrouche N, Herholz K, Mielke R, Holthoff V, Baron JC. 18FDG PET in vascular dementia: differentiation from Alzheimer's disease using voxel-based multivariate analysis. J Cereb Blood Flow Metab. 2006;26(9):1213-1221. (Pubitemid 44268183)
38. Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain. 1999;122(pt 8):1449-1468. (Pubitemid 29374123)
39. Suzuki M, Desmond TJ, Albin RL, Frey KA. Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Ann Neurol. 2002;51(6):767-771. (Pubitemid 34568857)
40. Walker Z, Costa DC, Walker RW, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002;73(2):134-140. (Pubitemid 41655939)
41. Gilman S, Koeppe RA, Little R, et al. Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Ann Neurol. 2004;55(6):774-780. (Pubitemid 38702572)
42. McKeith I, O'Brien J, Walker Z, et al; DLB Study Group. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6(4):305-313. (Pubitemid 46367938)
43. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319. (Pubitemid 38269583)
44. Villemagne VL, Fodero-Tavoletti MT, Pike KE, Cappai R, Masters CL, Rowe CC. The ART of loss: Aβ imaging in the evaluation of Alzheimer's disease and other dementias. Mol Neurobiol. 2008;38(1):1-15.
45. Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12(6):584-595. (Pubitemid 41031060)
46. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718-1725. (Pubitemid 46763260)
47. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528-1547.
48. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709- 7717.
49. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68(15):1205-1212.
50. Engler H, Santillo AF, Wang SX, et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2008;35(1):100-106. (Pubitemid 350234135)
51. Drzezga A, Grimmer T, Henriksen G, et al. Imaging of amyloid plaques ad cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage. 2008;39(2):619-633. (Pubitemid 350117638)
52. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71(12):903-910.
53. Li Y, Rinne JO, Mosconi L, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2008;35(12):2169-2181.
54. Roy CS, Sherrington CS. On the regulation of the blood supply of the brain. J Physiol. 1890;11(1-2):85-158, 17.
55. Sokoloff L. Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed Proc. 1981;40(8):2311-2316. (Pubitemid 11036104)
56. Raichle ME, Mintun MA. Brain work and brain imaging. Annu Rev Neurosci. 2006; 29:449-476.
57. 18F]FDG PET measures in differentiating dementias. J Nucl Med. 2005;46(6):936-944.
58. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer disease: report of NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34(7):939-944. (Pubitemid 14076461)
59. McKeith IG, Dickson DW, Lowe J, et al; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65(12):1863-1872. (Pubitemid 43970103)
60. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546-1554. (Pubitemid 28565230)
61. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256(3):183-194. (Pubitemid 39222988)
62. Koeppe RA, Frey KA, Kume A, Albin R, Kilbourn MR, Kuhl DE. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab. 1997;17(9):919-931. (Pubitemid 27396580)
63. Talariach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain: 3-D Proportional System - An Approach to Cerebral Imaging. New York, NY: Thieme Medical Publishers; 1988.
64. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med. 1994; 35(9):1528-1537. (Pubitemid 24280464)
65. Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr. 1995;19(4):541-547.
66. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36(7):1238-1248.
67. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69(9): 871-877. (Pubitemid 47329586)
68. Silverman DHS. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004;45(4):594-607.
69. Silverman DH, Gambhir SS, Huang HW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med. 2002;43(2):253-266.
70. 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49(3):390-398.
71. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med. 2000;41(11):1920-1928.
72. Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain. 2007;130(pt 10):2636-2645. (Pubitemid 47511719)
73. Rabinovici GD, Jagust WJ, Furst AJ, et al. Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64(4):388-401.
74. Rinne JO, Laine M, Kaasinen V, Norvasuo-Heilä MK, Någren K, Helenius H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology. 2002;58(10):1489-1493. (Pubitemid 34552954)